Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q2 Revenue: USD 16.41 M

Revenue: As of FY2025 Q2, the actual value is USD 16.41 M.

EPS: As of FY2025 Q2, the actual value is USD 0.45.

EBIT: As of FY2025 Q2, the actual value is USD -36.47 M.

Segment Revenue

• Journey Medical Corporation (JMC): Net product revenue was $15.0 million for the three months ended June 30, 2025, compared to $14.9 million for the same period in 2024. For the six months ended June 30, 2025, net product revenue was $28.1 million, compared to $27.9 million in 2024.

Operational Metrics

• Loss from Operations: The consolidated loss from operations was $36.5 million for the three months ended June 30, 2025, compared to $27.8 million for the same period in 2024. For the six months ended June 30, 2025, the loss from operations was $58.8 million, compared to $64.4 million in 2024.
• Research and Development Expenses: R&D expenses decreased to $8.1 million for the three months ended June 30, 2025, from $12.7 million in 2024. For the six months ended June 30, 2025, R&D expenses were $12.1 million, down from $37.5 million in 2024.
• Selling, General and Administrative Expenses: These expenses increased to $38.8 million for the three months ended June 30, 2025, from $20.8 million in 2024. For the six months ended June 30, 2025, these expenses were $64.4 million, up from $38.8 million in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $47.1 million, compared to $47.2 million in 2024.
• Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $56.7 million, compared to $42.1 million in 2024.

Unique Metrics

• Gain from Deconsolidation of Subsidiary: A gain of $27.1 million was recognized from the deconsolidation of Checkpoint due to its acquisition by Sun Pharma in May 2025.

Future Outlook and Strategy

• Core Business Focus: Fortress Biotech plans to continue focusing on acquiring and advancing assets to enhance long-term value through product revenue, equity holdings, and dividend and royalty revenue streams. The company aims to leverage its network to identify promising products for acquisition and development.
• Non-Core Business: The company is exploring strategic partnerships and collaborations to support research and development, including joint ventures and out-licensing opportunities.